Highlights Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Market Closed - Nasdaq Other stock markets 01:30:00 19/06/2024 am IST			5-day change	1st Jan Change
1,039 ^USD	-0.60%		+1.11%	+18.31%

18/06	Alvotech Enters Commercialization Deal for Eylea Biosimilars with Advanz Pharma	MT
17/06	Regeneron Pharmaceuticals Insider Sold Shares Worth $1,596,400, According to a Recent SEC Filing	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Alvotech Enters Commercialization Deal for Eylea Biosimilars with Advanz Pharma	18/06	MT
Regeneron Pharmaceuticals, Inc. Announces 14-Month Median Follow-Up Data from the Pivotal Phase 1/2 Linker-MM1 Trial of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma	16/06	CI
Regeneron Pharmaceuticals Wins Injunctions Against Biosimilars to Eye Disease Drug Eylea	15/06	MT
Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Has Approves Kevzara®	11/06	CI
FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier	04/06	MT
Fibrogen, Inc. Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals, Inc. to Evaluate FibroGen's Immuno-Oncology Assets, Fg-3175 (Anti-Ccr8), in Upcoming Clinical Trials	04/06	CI
EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review	31/05	RE
Regeneron Pharmaceuticals, Sanofi Say Dupixent FDA Application Decision Delayed by 3 Months	31/05	MT
Regeneron Pharmaceuticals, Inc and Sanofi Announce Dupixent® Recommends for EU Approval by the CHMP to Treat Patients with COPD	31/05	CI
Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® for the Treatment of COPD Patients with Type 2 Inflammation	31/05	CI
Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer	24/05	MT
Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075	24/05	CI
Regeneron, Sanofi Disclose Positive Results for Lung Disease Treatment Candidate	21/05	MT
Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine	20/05	CI
Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $1,000.25	20/05	MT
Sector Update: Health Care Stocks Mixed Late Afternoon	18/05	MT
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Younger CRSwNP Group	13/05	DJ
Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Dupixent	13/05	CI
Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks	08/05	CI
Global markets live: Etsy, Qualcomm, Carvana, Rio Tinto, Apple...	02/05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Highlights

Filters